Skip to main content
Andrew Davis, MD, Oncology, Florissant, MO

AndrewAdam BernDavisMD

Oncology Florissant, MO

Physician

Dr. Davis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Davis' full profile

Already have an account?

  • Office

    1255 Graham Rd
    # Dv
    Florissant, MO 63031
    Phone+1 800-647-2098
    Fax+1 314-362-3192

Education & Training

  • McGaw Medical Center of Northwestern University
    McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 2014 - 2017
  • Northwestern University The Feinberg School of Medicine
    Northwestern University The Feinberg School of MedicineClass of 2014

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 2014 - 2026
  • MO State Medical License
    MO State Medical License 2020 - 2025
  • IA State Medical License
    IA State Medical License 2014 - 2021
  • American Board of Internal Medicine Internal Medicine

Publications & Presentations

PubMed

Lectures

  • A prospective study tracking longitudinal changes in genome-wide cell-free DNA (cfDNA) methylation to identify early nonresponders to cancer treatment. 
    2019 ASCO Annual Meeting - 6/1/2019
  • Whole-genome cell-free DNA (cfDNA) changes as a dynamic blood-based biomarker for early response assessment of advanced tumors. 
    2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

  • Guardant Health and Washington University to Present Study at 2024 ASCO Meeting Highlighting Utility of ctDNA to Address Racial Inequities in the Use of Targeted Therapies and Enrollment in Clinical Trials
    Guardant Health and Washington University to Present Study at 2024 ASCO Meeting Highlighting Utility of ctDNA to Address Racial Inequities in the Use of Targeted Therapies and Enrollment in Clinical TrialsJune 3rd, 2024